Maximal androgen blockade: Facts and fallacies

Endocrine-Related Cancer

Volumn 5, Issue 4, 1998, Pages 353-356

  Denis, L J ^a  

^a Oncology Centre of Antwerp   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CYPROTERONE; DIETHYLSTILBESTROL;

ARTICLE; CANCER SURVIVAL; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HORMONAL THERAPY; ORCHIECTOMY; PROSTATE CANCER; RECEPTOR BLOCKING; TUMOR GROWTH;

EID: 0032417569     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0050353     Document Type: Article

References (23)

1. Blackard CF 1975 The Veterans Administration Cooperative Urological Research Group studies of carcinoma of the prostate: a review. Cancer and Chemotherapy Reports 59 225-232.
2. Bracci U 1979 Anti-androgens in the treatment of prostatic cancer. European Urology 5 303-306.
3. Caubet JF, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Ernstoff MS & Ross SD 1997 Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal anti-androgens. Urology 49 71-78.
4. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA & Goodman PJ 1989 A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New England Journal of Medicine 321 419-424.
5. Denis LJ 1993 Staging and prognosis of prostate cancer. European Urology 24 13-19.
6. Denis L & Murphy GP 1993 Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 72 3888-3895.
7. Denis LJ, Whelan P, Carneiro de Moura JL, Newling D, Bono A, De Pauw M, Sylvester R & Members of the EORTC GU Group and EORTC Data Center 1993 Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology 42 119-129.
8. Huggins C & Hodges CV 1941 Studies in prostate cancer. 1. The effects of castration, of oestrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research 1 293-297.
9. Kaisary AV, Tyrell CJ, Peeling WB & Griffiths K 1991 Comparison of LHRH analogues with orchiectomy in patients with metastatic prostate cancer. British Journal of Urology 67 502-508.
10. Labrie F, Dupont A, Belanger A, Levebre FP, Cusan L & Raynaud JP 1983 New hormonal therapy in prostate cancer: combined use of a pure anti-androgen and an LHRH agonist. Hormone Research 20 18-27.
11. Nesbit RM & Baum WC 1995 Endocrine control of prostatic carcinoma. Clinical and statistical survey of 1818 cases. Journal of the American Medical Association 143 1317-1320.
12. Oosterlinck W, Mattelaer J, Casselman J & Van Velthoven R 1997 PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Acta Urologica Belgica 65 63-71.
13. Pavone-Macaluso M, de Voogt HJ, Viggiano G, Barasolo E, Lardennois B, De Pauw M & Sylvester R 1986 Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomised phase III trial of the EORTC GU Group. Journal of Urology 136 624-631.
14. Prostate Cancer Trialists' Collaborative Group 1995 Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. The Lancet 346 265-269.
15. Robinson MRG, Smith PH, Richards B, Newling DWW, De Pauw M & Sylvester R 1995 The final analysis of the EORTC GU Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. European Urology 28 273-283.
16. Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang WJ, Schellhammer JJ & Kolvenbag GJCM 1997 Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology 50 330-336.
17. Scher HI & Kolvenbag GJCM 1997 The antiandrogen withdrawal syndrome in relapsed prostate cancer. European Urology 31 3-7.
18. Schulze H & Senge T 1990 Influence of different types of anti-androgens on luteinizing hormone releasing hormone analogue-induced testosterone search in patients with metastatic carcinoma of the prostate. Journal of Urology 144 934-941.
19. Smith PH, Suciu S, Robinson MRG, Richards B, Bastable JRG, Glashan RW, Bouffioux C, Lardennois B, Williams RE, De Pauw M & Sylvester R 1986 A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the EORTC. Journal of Urology 136 619-623.
20. Sogani PC, Vagawara MR & Whitmore WF 1984 Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer 54 744-750.
21. Sylvester RJ, Denis L & de Voogt H, for the EORTC GU Group 1998 The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Urology 33 134-143.
22. The Leuprolide Study Group 1984 Leuprolide versus DES for metastatic prostate cancer. New England Journal of Medicine 311 1281-1287.
23. de Voogt HJ, Studer U, Schröder F, Klyn JG, de Paur M, Sylvester R & members of the EORTC GenitoUrinary tract Cancer Cooperative Group 1998 Maximum androgen blockade using LHRH A buserelin in combination with short term (two weeks) or long term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. European Urology 33 152-158.